tradingkey.logo
tradingkey.logo
Search

GRI Bio Reports 6-Week Interim Lung Function Data In Ongoing Phase 2A Study In Idiopathic Pulmonary Fibrosis

ReutersSep 11, 2025 2:11 PM
facebooktwitterlinkedin

- GRI Bio Inc GRI.O:

  • GRI BIO REPORTS 6-WEEK INTERIM LUNG FUNCTION DATA IN ONGOING PHASE 2A STUDY IN IDIOPATHIC PULMONARY FIBROSIS (“IPF”)

  • GRI BIO INC - GRI-0621 SHOWS NO WORSENING OF FVC AT 6 WEEKS

  • GRI BIO INC - PHASE 2A STUDY FULLY ENROLLED; TOPLINE DATA EXPECTED Q3 2025

  • GRI BIO INC - NO SAFETY CONCERNS OBSERVED BY IDMC IN GRI-0621 STUDY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI